Results 21 to 30 of about 2,943 (200)
Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels. [PDF]
Br J Clin PharmacolThis review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene–drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or ...
Suarez-Kurtz G.
europepmc +2 more sources
Pathogens, 2022 Although tafenoquine was highly effective for eliminating microscopically detectable parasitemia in mouse models of Babesia microti infection, all of the mice which were assessed developed a relapse of infection, except for those which had been treated ...
Prithiv J. Prasad, Gary P. Wormser
doaj +1 more source
A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. [PDF]
PLoS ONE, 2017 Tafenoquine is an investigational 8-aminoquinoline for the prevention of Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more convenient dosing, compared with the currently recommended 14-day primaquine regimen.This ...
Mark M Fukuda +11 more
doaj +1 more source
Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review
Malaria Journal, 2020 Background Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200 mg
Stephan Duparc +4 more
doaj +1 more source
Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial [PDF]
Antimicrobial Agents and Chemotherapy, 2018 Tafenoquine is a novel 8-aminoquinoline antimalarial drug recently approved by the U.S. Food and Drug Administration (FDA) for the radical cure of acutePlasmodium vivaxmalaria, which is the first new treatment in almost 60 years.
Nilay Thakkar +5 more
openaire +2 more sources
Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model [PDF]
, 2015 The undetectable hypnozoite reservoir for relapsing Plasmodium vivax and P. ovale malarias presents a major challenge for malaria control and elimination in endemic countries.
Bassat, Quique +19 more
core +11 more sources
eLife, 2022 Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax malaria. The mechanism of action and optimal dosing are uncertain.
James A Watson +12 more
doaj +1 more source
Molecules, 2022 Analytical methods for the quantification of the new 8-aminoquinoline antimalarial tafenoquine (TQ) in human blood, plasma and urine, and the 5,6-orthoquinone tafenoquine metabolite (5,6-OQTQ) in human plasma and urine have been validated.
Geoffrey W. Birrell +6 more
doaj +1 more source
PLoS Medicine, 2021 BackgroundDespite recent intensification of control measures, Plasmodium vivax poses a major challenge for malaria elimination efforts. Liver-stage hypnozoite parasites that cause relapsing infections can be cleared with primaquine; however, poor ...
Narimane Nekkab +8 more
doaj +1 more source
Tafenoquine for Plasmodium vivax malaria
Indian Journal of Medical Research, 2021 Plasmodium vivax (P. vivax) malaria is a major problem in various countries such as America, Southeast Asia, Africa and the Eastern Mediterranean. The major barrier in controlling P. vivax malaria is its ability to remain in the liver as a hypnozoite form which is responsible for relapse of P.
Sharma, Jatin +3 more
openaire +2 more sources